Triple

Target class: orphan medicinal products legislation
Context triple: [Regulation (EC) No 141/2000 on orphan medicinal products, instanceOf, orphan medicinal products legislation]

• A. orphan drug
  An orphan drug is a pharmaceutical product developed specifically to diagnose, prevent, or treat a rare disease or condition that affects a small percentage of the population, often incentivized by special regulatory and financial benefits.
• B. organ of the European Medicines Agency
  An organ of the European Medicines Agency is a formal decision-making or advisory body within the EMA’s governance structure, such as its Management Board, Executive Director, or scientific committees, responsible for specific regulatory, administrative, or scientific functions.
• C. pharmaceutical law chosen
  Pharmaceutical law is the body of legal rules and regulations governing the research, development, approval, manufacturing, marketing, distribution, and use of drugs and medical products to ensure their safety, efficacy, and ethical oversight.
• D. medicinal product
  A medicinal product is a substance or combination of substances presented as having properties for treating or preventing disease in humans or animals, or administered with the aim of restoring, correcting, or modifying physiological functions or making a medical diagnosis.
• E. organ of the International Council for Harmonisation
  An organ of the International Council for Harmonisation is a formal body or component within the ICH structure that is responsible for developing, coordinating, or overseeing international guidelines and activities related to the harmonisation of pharmaceutical regulation.
• F. None of above.